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Abstract
Background: Recruitment to randomised controlled trials (RCTs) with very different treatment arms is often
difficult. The ProtecT (Prostate testing for cancer and Treatment) study successfully used qualitative research
methods to improve recruitment and these methods were replicated in five other RCTs facing recruitment
difficulties. A similar qualitative recruitment investigation was undertaken in the SPARE (Selective bladder
Preservation Against Radical Excision) feasibility study to explore reasons for low recruitment and attempt to
improve recruitment rates by implementing changes suggested by qualitative findings.
Methods: In Phase I of the investigation, reasons for low levels of recruitment were explored through content
analysis of RCT documents, thematic analysis of interviews with trial staff and recruiters, and conversation analysis
of audio-recordings of recruitment appointments. Findings were presented to the trial management group and a
plan of action was agreed. In Phase II, changes to design and conduct were implemented, with training and
feedback provided for recruitment staff.
Results: Five key challenges to trial recruitment were identified in Phase I: (a) Investigators and recruiters had
considerable difficulty articulating the trial design in simple terms; (b) The recruitment pathway was complicated,
involving staff across different specialties/centres and communication often broke down; (c) Recruiters inadvertently
used ‘loaded’ terminology such as ‘gold standard’ in study information, leading to unbalanced presentation; (d)
Fewer eligible patients were identified than had been anticipated; (e) Strong treatment preferences were expressed
by potential participants and trial staff in some centres. In Phase II, study information (patient information sheet
and flowchart) was simplified, the recruitment pathway was focused around lead recruiters, and training sessions
and ‘tips’ were provided for recruiters. Issues of patient eligibility were insurmountable, however, and the
independent Trial Steering Committee advised closure of the SPARE trial in February 2010.
Conclusions: The qualitative investigation identified the key aspects of trial design and conduct that were
hindering recruitment, and a plan of action that was acceptable to trial investigators and recruiters was
implemented. Qualitative investigations can thus be used to elucidate challenges to recruitment in trials with very
different treatment arms, but require sufficient time to be undertaken successfully.
Trial Registration: CRUK/07/011; ISRCTN61126465
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Randomised controlled trials (RCTs) often encounter
recruitment difficulties, even when the interventions
appear relatively uncontroversial [1]. RCTs including a
surgical arm face particular challenges [2,3]. A major
challenge is that unless surgical procedures are being
compared with each other, the comparison arm is likely
to be very different [4]. Considering randomisation
between surgery and another treatment such as radio-
therapy, chemotherapy or some form of delayed inter-
vention or monitoring is often difficult for clinicians and
patients. Clinicians have to come to terms with the fact
that there is uncertainty/equipoise about treatments
they may have been recommending for some time and
accept that the treatments have not been robustly evalu-
ated and so may not be the most effective or cost-effective.
Participating in the RCT is likely to mean collaboration
and coordination with colleagues in other specialties
where the culture may be somewhat different. For
patients, the idea that there is uncertainty over the com-
parative effectiveness of such different interventions - that
such different treatments may lead to similar long term
outcomes, particularly when short-term side effects are
very different - can be very difficult to accept. When the
disease being treated is cancer, with strong lay beliefs and
connotations of ‘life and death’, RCTs involving a compari-
son of surgical procedures with other techniques are
fraught with difficulties.
However, in many areas of cancer treatment/therapy,
there is uncertainty over the most effective treatment,
and often the most controversial questions focus in
areas where the alternatives may include a surgical
option. For example, in muscle invasive bladder cancer,
most research has focussed on individual aspects of the
two main modes of treatment: radical surgery (cystect-
omy - removal of the bladder) or conservative treatment
based on radiotherapy (either alone or as part of a pro-
gramme of selective-bladder preservation [SBP] where
radiotherapy is used in those with good response to
neo-adjuvant chemotherapy and cystectomy is per-
formed in poor responders). Case series (with all their
attendant flaws) have demonstrated similar survival out-
comes for contemporary cystectomy, radiotherapy and
SBP approaches, but the need for rigorous evidence in
the form of a randomised phase III trial to demonstrate
that these approaches are comparable has recently been
very strongly encouraged [5].
The SPARE (Selective bladder Preservation Against
Radical Excision) trial (CRUK/07/011; ISRCTN61126465)
was set up to compare radical surgery with SBP in
patients with muscle invasive transitional cell carcinoma
of the bladder. The primary objective was to demonstrate
that SBP was not-inferior to surgery in terms of overall
survival and this required a sample size of 1015 patients.
It was anticipated that this would be a difficult trial
because of the comparison between surgery and radio-
therapy, and so a study to investigate the feasibility of
recruitment began in July 2007 and included a qualitative
study of patient perceptions and experiences [6]. Recruit-
ment proceeded slowly and failed to meet original feasi-
bility targets. In April 2009, with the support of the
independent Trial Steering Committee (TSC), the Trial
Management Group’s (TMG) request to the Funder to
extend the feasibility study by one year was approved and
a target accrual rate of at least 6 patients per month was
set, to be achieved prior to completion of the three year
feasibility phase. At that point, 34 patients (out of a target
110) had been recruited over a period of 22 months. A
focussed qualitative study of recruitment issues was
initiated by the Chief Investigator and the TMG to try to
identify any difficulties that might be amenable to
improvement, albeit within a very tight timescale. This
recruitment investigation built on findings from similar
studies in other RCTs [7-9] and was based on the appli-
cation of an adaptation of a complex intervention to
improve recruitment [10]. This paper reports on the find-
ings of this qualitative recruitment investigation.
Methods
The qualitative recruitment investigation comprised two
iterative and overlapping phases of data collection, data
analysis, feedback and training (Table 1). The design
was based broadly on the ProtecT (Prostate testing for
cancer and Treatment) complex recruitment interven-
tion [10], but with adaptations suggested by the results
from similar applications of qualitative research to
improve recruitment in five other RCTs [7]. The two-
stage design of the recruitment investigation in the
SPARE RCT comprised a firstp h a s eo fi n t e n s i v ed a t a
collection and analysis to investigate the issues that
were leading to low levels of recruitment and an ‘inter-
vention’ phase to improve recruitment. Detailed research
methods are described below.
Phase I
Ethical approval was gained from the South East
Research Ethics Committee (Reference number: 06/
MRE01/95) to conduct the recruitment investigation as
an integrated part of the SPARE feasibility study, as
recommended by de Salis et al. [7]. Data collection and
analysis began immediately, including:
1. Document reviews
The recruitment investigation team (SP and JLD) inter-
r o g a t e dt h eS P A R Et r i a lp r o t o c o la n de x a m i n e dt h e
SPARE trial Patient Information Sheet (PIS) to investi-
gate whether any aspects were unclear or potentially
open to misinterpretation. A rapid literature search
identified a recent review in the Lancet summarising
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marise aspects of the trial protocol concerned with elig-
ibility and recruitment, and identify any potentially
misleading sections in the PIS [11-13].
2. In-depth interviews
Two interview topic guides were developed, based on
those used in previous studies [7], one for the main
SPARE TMG team closely involved in the design and
coordination of the trial: chief investigator, scientific
lead, a major clinical contributor, and the trial manager;
and another for those who directly recruited patients
including clinicians, research fellows and research
nurses. All interviews were conducted by SP after
obtaining informed consent. Interviewees were asked
about the background and purpose of the trial; their
role in the trial; recruitment training they had received;
the SPARE recruitment pathway, including its processes
and any difficulties; structural and organisational issues;
and their views about the trial treatments and randomi-
sation, the importance of the trial and how to improve
recruitment. In addition, interviewees who were recrui-
ters were also asked about how they introduced the trial
and explained randomisation in appointments already
conducted, recruitment strategies used, acceptability of
the trial design and their satisfaction with the adequacy
of the discussion and outcome of the appointments.
Interviews were conducted purposively - first with mem-
bers of the SPARE TMG, then clinicians/nurses involved
in recruitment, and then with recruiters in centres not
involved in the SPARE TMG.
Thematic analysis, using techniques of constant com-
parison, was undertaken by SP on transcripts of in-
depth interviews. This involved comparing emerging
themes and codes within transcripts and across the
dataset [14,15]. The coding carried out using ATLAS-ti
qualitative data analysis software was cross-checked by
JLD and inconsistencies resolved. Descriptive accounts
were produced by SP and discussed with JLD.
3. Audio recording of discussions between potential RCT
participants and recruitment staff
Audio recording of recruitment appointments had been
shown to be extremely important for understanding key
issues in the ProtecT study [16], but was found to be
very difficult to operationalise in other RCTs [7]. Eight
digital recorders were delivered to seven centres partici-
pating in SPARE with documents explaining the ethical
requirements and instructions for use, and strong
encouragement was given by the TMG to record
appointments. Data analysis included thematic methods
(as described above for interviews) and targeted conver-
sation analysis to identify problematic aspects of interac-
tions [16].
4. Details collected in SPARE trial screening logs
Clinical centres open for recruitment to SPARE were
asked to keep detailed logs of patients who were investi-
gated for trial eligibility to record what happened to
them, including reasons for including/not including
them in recruitment and any reasons given for declining
involvement. They were also asked to document the
recruitment pathways of patients, beginning from the
diagnosis of bladder cancer to making a decision about
participating in the SPARE trial. Simple counts, cross
tabulations and content analysis were combined to sum-
marise the data [12] and describe the recruitment
pathways.
Phase II
This phase commenced with a meeting between the
recruitment investigation team and leading members of
the SPARE TMG, including patient representatives, at
which a summary of anonymised findings from Phase I
were presented by JLD. The findings are detailed in the
results, below, and were used to draw up a plan of
action for Phase II which was agreed between the
Table 1 SPARE trial qualitative recruitment investigation
- design and progression
Time period





















































The qualitative recruitment investigation comprised two iterative and
overlapping phases - a first phase of intensive data collection and analysis to
investigate the issues that were leading to low levels of recruitment and an
’intervention’ phase to improve recruitment through feedback and training.
The investigation carried out over 10 months is represented in Table 1.
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comprised:
1. A new version of the PIS including a simpler ver-
sion of the study flowchart.
2. A programme of activity to try to increase recruit-
ment, including:
a. A document of ‘tips for recruitment’ based on the
one used in the ProtecT complex intervention, but
adapted specifically for SPARE based on the findings
of the recruitment study.
b. Dedicated training sessions for clinical centre staff
working on SPARE.
The impact of Phase II was evaluated observationally
through simple counts of recruited participants and with
qualitative (thematic) analysis of comments made by
clinicians and recruiters in SPARE who had read the
‘tips’ document and/or attended the training sessions.
Results
The Phase I data collected from the in-depth interviews,
documents, tape recordings and screening logs were
analysed first. The content analysis of the trial protocol,
PIS and recent review publication [5] provided impor-
tant background information. The first set of interviews
comprised seven participants, six of whom were mem-
bers of the main trial team, and included three oncolo-
gists. Four participants, including two urologists
(surgeons) were then recruited from non-TMG centres.
In total nine recruiters and two non-recruiters were
interviewed across four centres. Although clear instruc-
tions were provided and the recruiters took away the
recorders enthusiastically, only four audio-recordings of
recruitment appointments were made. The reasons for
the limited number of recordings were not expressed
clearly in this study, but were likely to be similar to
those found elsewhere [7], with additional difficulty in
SPARE because of the complicated and prolonged
recruitment period (see below). Simple counts and con-
tent analysis of screening logs revealed that numbers of
eligible patients varied considerably between recruitment
centres, partly due to the variations in how systemati-
cally the screening logs were maintained in each centre.
Less than half (43.4%) of patients screened were deemed
potentially eligible for the SPARE trial, and less than a
half (43.3%) of those were actually approached to dis-
cuss the trial (Table 2). ‘Treatment preferences’ were
the most commonly reported reasons for refusal to be
randomised (73.7%). In most centres, patients appeared
to favour (or disfavour) one arm in particular, and over-
all there was an indication of greater preference for
bladder preservation (58.9%) than for surgery (30.4%).
The qualitative analyses of the data gained during
Phase I presented a clear picture of the recruitment
issues. In particular, there were two key issues compris-
ing five challenges that hindered recruitment to the
SPARE trial - the first had its origins in detailed aspects
of the trial design and conduct; the second involved the
difficulties recruiters experienced because of their per-
ception that patients had clear treatment preferences.
These key issues are outlined below, followed by a
description of the plan for Phase II, and its brief
evaluation.
Key recruitment issues in the SPARE trial
1. SPARE trial design and conduct
The design of the SPARE trial was not easily described
by any of the investigators or recruiters in the in-depth
interviews, and interviewees and the recruitment investi-
gation team felt the PIS contained several aspects that
were potentially confusing. This made attempts to
recruit participants very difficult. There were four major
issues:
(a) Complexity of trial design Several linked aspects of
the study design needed to be described to patients,
including the need for neo-adjuvant chemotherapy, the
timing of randomisation in relation to the cycles of
Table 2 SPARE trial screening log summary information
Total no. of patients considered for
SPARE (22 centres; 22 months)
585
Ineligible 331 (56.6%)
Potentially eligible 254 (43.4%)
A. Approached 110 (43.3%)
1. Recruited 34 (30.9%)
2. Declined 76 (69.1%)
Due to preference 56 (73.7%)
Surgery 17 (30.4%)
Radiotherapy/No surgery 33 (58.9%)
No chemo 6 (10.7%)
Unknown/Other 20 (26.3%)
B. Not approached 105 (41.3%)
1. Due to preference 28 (26.7%)
Surgery 11 (39.3%)
Radiotherapy/No surgery 10 (35.7%)
No chemo 7 (25%)
2. Clinical Decision 22 (20.9%)
3. Unknown/Other 55 (52.4%)
Pending 39 (15.4%)
Clinical centres open for recruitment to SPARE were asked to keep detailed
logs of patients who were investigated for trial eligibility to record what
happened to them, including reasons for including/not including them in
recruitment and any reasons given for declining involvement. The analysis of
these data is shown in Table 2.
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either surgery to remove the cancer and bladder, or a
policy (SBP) that involved radiotherapy to destroy the
cancer and preserve the bladder except where the
tumour persisted when surgery was recommended.
There was also discussion of the need for repeated
cycles of chemotherapy and a final cystoscopy in the
SBP arm that would determine the need for surgery or
not. Recruiters and investigators agreed that the SPARE
trial was difficult to explain:
P4: The other trials that I work on that are rando-
mised are usually working say between two different
types of chemotherapy (...) and no, I haven’t had pro-
blems with patients going into studies like that. I
think it’s the fact that it is sort of the radical choice
if you like, surgery-no bladder, bladder preservation-
keep your bladder (Nurse, Recruiter).
P5: I think one of the important things to get across
to them is that we are only discussing what’ll happen
if they had a good response to chemotherapy, and
making it quite clear that if they don’t have a good
response to chemotherapy, then we’db eo f f e r i n g
cystectomy anyway, because a couple of the patients
I’ve seen have been a bit confused about the fact that
they think that regardless of what happens with the
chemotherapy, they still have a choice between the
two, so making it very clear that we don’tk n o w
whether you’r eg o i n gt ob ei nt h i sr a n d o m i s a t i o n
until you’ve had that post-chemo cystoscopy (Oncolo-
gist, Recruiter).
A recorded explanation of the SPARE trial given to a
patient illustrates how difficult it was to explain and fol-
low:
P12: You’ve got this sort of bladder cancer, a man of
your age, they say what you should have is having
the bladder removed for the cancer. Um and the che-
motherapy then, you know, we would suggest you
add to that. Uh and as I say, that is the gold stan-
dard way of dealing with the treatment, with that
approach (...).
Patient: Mmm.
P12: The other approach that we’re testing in this
trial and what we’re doing is seeing whether this
approach works as well as um, is seeing whether we
can, instead of doing an operation, whether we can
use radiotherapy to sterilise the bladder. We have
used radiotherapy on and off but the concern has
always been about how successful it is at actually
getting rid of the cancer 100%. So what we’re doing
within this trial is testing whether or not, compared
to having surgery, whether or not we could select
people who’ve had chemotherapy. So if you get this
part of the treatment, you would be randomised to
having radiotherapy treatment if the cancer’sg o n e
after your chemotherapy compared to um, and if the
cancer hasn’t gone you still have surgery (...).
Patient: Mmm.
P12: This approach we call selective bladder preser-
vation. At the moment, we have no idea how that
stacks up against surgery in terms of how good it is.
Patient: Mmm.
P12: If we could show that that approach was as
good as surgery then it may be that’db eaq u i t ea n
attractive treatment, but, and it may sound an
attractive treatment but you know our first mission is
to cure you, the second is to cure you in the best pos-
sible way we can.
Patient: Mmm...hmm.
P12: So you could certainly argue the most certain
way of doing that is to do the surgery, um a less cer-
tain way might be to do radiotherapy, but you might
have the advantage of not needing this big operation
(Recruiter, recruiter-patient interaction).
The complexity of the trial design led to confusion
among some recruiters about the timing of randomisa-
tion:
P10: I explain to them that they would normally
come up against randomisation if the initial cysto-
scopy after 2 cycles is it, 3 cycles, 2 cycles I think, was
positive (Surgeon, Recruiter).
Recruiters indicated that they found the quantity of
information problematic as well as its complexity:
P4: I felt it really difficult and almost embarrassed at
times with the amount of information, not just the
SPARE information sheet which is, you know, quite
wordy, quite lengthy, and then the biological samples,
and then the quality of life, and the qualitative
study. You just thought, ‘g o s h ,t h i si sa w f u l ’,b e c a u s e
they’ve also just been given information on gemcita-
bine and cisplatin and the side effects, they’ve just
been informed that their bed’s been booked for this, I
mean it’s a huge amount to take on, and I think that
sometimes it’sm o s tp r o b a b l yj u s te a s i e rj u s tt os a y
‘no’, than to think about it (...) it’s really difficult
having to sort of bombard patients very early on with
so many different information sheets and consent
forms (Nurse, Recruiter).
(b) Recruitment pathway Recruiters were asked to
describe the pathway that potential trial participants fol-
lowed from a diagnosis of bladder cancer to being
recruited to the SPARE trial. In all centres this proved
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ber of people who might come into contact with the
patient during their visits and sometimes the different
clinical (surgery or oncology, or local/regional) centres
that might be involved:
P3: I think what we didn’t appreciate was the num-
ber of the different pathways with which people actu-
ally come into that system, and the complexity (...) in
terms of the treating centres and the randomising
centres and all the different centres that are involved
in an individual patient’s care (Investigator).
P1: You may have multiple different people involved
in the patient’s care, all of whom may give a slightly
different spin on the information, and some might be
very heavily involved in the trial and some people
might be very peripheral to it (...) different teams do
different parts of the treatment, is that some parts of
the team might be more committed than other parts
of team (Oncologist, Recruiter).
Recruiters also believed that some teams or members
were very committed to SPARE but that others were
indifferent or even antagonistic to it, and this created
additional difficulties because patients developed strong
preferences for one arm or the other:
P1: Patients have had very fixed ideas about what
treatment they want, which is I think a consequence of
not having the whole team on board and that can hap-
pen at centres where they’re referred in from outside, so
they’ve spoken to a urologist about surgery before any-
one even thought about SPARE. So the patient’sp r i m e d
for one particular treatment before they even get into
the SPARE centre (Oncologist, Recruiter).
P9: In my view the patient gets a bias towards sur-
gery from the start (...) The patient tends to hang on
to the first thing, so even if the patient gets to a
radiotherapist (...) they quite often say, “oh yes, I’ll
have surgery” even if they get to the radiotherapist.
By the time they get to me for what is supposed to be
the pros and cons and the discussions around rando-
misation, they quite often have things set in their
mind (Oncologist, Recruiter).
(c) Terminology The protocol and PIS presented a clear
story about the treatments offered in the SPARE trial in
terms of their history:
PIS, v.5: For many years the standard treatment for
bladder cancer has been with immediate surgery
removing the whole of the bladder - this is called
cystectomy (...). Radiotherapy has been used as an
alternative treatment to surgery. This is a new
approach to the treatment of bladder cancer (...).
Selective bladder preservation seems an attractive
option but we do not know if it is as safe and suc-
cessful as standard treatment (surgery).
This presentation was reflected by investigators and
recruiters, but they consistently added the terms ‘gold
standard’ and ‘experimental’:
P1: I normally talk about the fact that we need to do
chemotherapy ... and that the surgery is the ‘gold
standard’ way of managing the cancer and that there
is a possibility of the selective bladder preservation
possibly being an alternative, but we need to confirm
that in the trial and that’sw h yw e ’re doing a trial
(Oncologist, Recruiter).
P6: They’re either having the ‘gold standard’ treat-
ment or an experimental treatment (Nurse, Recruiter).
P5: Both of these treatments outside of the trial are
being used, and although the ‘gold standard’ is the
cystectomy, I think it’s a very important trial, because
there’s plenty of people opting for selective bladder
preservation, but without comparison, we really don’t
know how they compare (Oncologist, Recruiter).
The terms ‘gold standard’ and ‘experimental’ are inter-
esting because, as with other terms used in RCTs, they
are ‘loaded’ with meaning [16]. Two recruiters had some
insight into the potential impact of the terms:
P7: I have taken quite a firm approach in what we would
say is the accepted standard treatment and with the gui-
dance notes that (the TMG) sent out to investigators,
that’s the approach that (was) suggested to investigators
to take. Because originally we had a lot of patients pre-
ferring radiotherapy rather than surgery, so (TMG)
issued the guidance documents after an investigators
meeting (...) over a year ago where (it was) said, “it
should be emphasised that the ‘gold standard’ treatment
internationally is still cystectomy” and I think then we
had a little bit of a backlash where may be we were sell-
ing it too much and so more (laughing) patients decided
to go down the cystectomy arm (Oncologist, Recruiter).
P1: Certainly in my experience (there is an overall
preference among patients for the SBP arm),b u t
whether that is something that we’re unconsciously
telling patients and... they’re reading those signs...
(Oncologist, Recruiter).
The similarity of these phrases to other ‘loaded’ terms
in other RCTs [16] meant that these were identified as
key issues to address in a redrafted PIS and advice to
recruiters in Phase II.
(d) Eligibility issues As indicated above, the screening
logs revealed that only small numbers of patients were
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even amongst those who were eligible, many were not
approached about the trial, and only a very small num-
ber agreed to consider randomisation. Reasons for this
included the complexity of the eligibility criteria:
P7: Few eligible patients, well, far fewer than we ori-
ginally thought and it’s the eligibility for chemother-
apy, fitness for chemotherapy, some patients who are
not radiotherapy candidates because of specific things
like, they’ve got a lot of non-tumor associated carci-
noma-in-situ (Oncologist, Recruiter).
The small numbers also meant that recruiters prob-
ably forgot about SPARE:
P2: I think there are less patients who are eligible
than was originally anticipated when it was designed,
because patients may be fit for surgery, but they
might not be fit for chemotherapy and vice versa (...)
then because of that, it makes it harder for people to
may be keep it in their forefront of their minds, they
might not realise that it’s potential SPARE patient
until too late (Investigator).
Some recruiters thought there was leeway for interpre-
tation of the inclusion/exclusion criteria in partnership
with the main trial team while others felt that these cri-
teria were set in stone:
P9: I personally don’t have a problem (with applying
the eligibility criteria), but that’s because I deal with
trials all the time (...). I’m used to the fact that
there’s sometimes a little bit of leeway and room for
interpretation and that we can always check with the
principal investigator, but I think with some of my
colleagues, both juniors within oncology and collea-
gues in surgery are not as familiar with trials, maybe
have a little more difficulty in interpretation (Oncolo-
gist, Recruiter).
P10: Well no, but (inaudible) exclusion criteria,
they’re kind of set in stone, aren’t they. I wouldn’t
expect anybody, central person in the trial to encou-
rage variance from their own exclusion criteria,
would you? (Surgeon, Recruiter).
In summary, several aspects of the design and conduct
of SPARE came together to make recruitment difficult.
There was also another major difficulty - treatment pre-
ferences expressed by patients.
2. Treatment preferences
Recruiters and investigators repeatedly mentioned that
they were convinced that a major barrier to recruitment
to SPARE was the existence of clear treatment prefer-
ences among patients:
P1: I think I was surprised about the strength of feel-
ing many people have about personal autonomy (...).
The biggest handicap in terms of recruitment has
been people saying I want one specific treatment for
one particular reason or this treatment’s right for me
or not (Oncologist, Recruiter).
P9: Either people want it [the cancer/bladder] out
desperately, don’t want to talk about anything unless
it’s out, they want rid of it. Or the group of patients
that really doesn’tp a n d e rt ot h ei d e ao fab i go p e r a -
tion and want to hang on to their bladder, they want
to be normal. And so I find a lot of patients come
along, even if they haven’t been influenced by some-
body else, even if the trial has been put to them
beautifully, they usually have some kind of preference
based on what happens to them rather than on the
effects or the efficacy of the treatment, and I think
that’s the biggest problem from the patient’sp o i n to f
view (Oncologist, Recruiter).
Some thought that patients’ preferences were influ-
enced by others involved in the recruitment pathway:
P6: Depends who’ss p o k e n(laughs lightly) to them
first, I mean if the surgeons have spoken to them first,
they generally think that surgery is the best option
because it’s been discussed by a surgeon and to a sur-
geon that is the best option. If they’ve spoken to an
oncologist or myself, if they speak to me, they tend to
be more open-minded about it, because I present both
sides. It’s quite difficult to get people onto a trial say-
ing, ‘hey lets see if it’s alright to not have surgery’,
when the surgeons are saying, ‘well I’d have surgery’.
It’s not that (surgeon) is anti-trial or anything else,
because he’s not... he’sv e r yp r ot r i a l s ,b u th i sf u n d a -
mental belief is that if you’ve got a bladder cancer you
should have your bladder taken out (Nurse, Recruiter).
P2: Some people, urologists especially, in some centres
are not behind the trial at all, and will not put patients
in towards it, so some centres I know haven’t recruited
because there’s a problem with the urologist. Clinicians
in general are doing what they think is best, so surgeons
are very defensive of cystectomy because they’ve done
lots of them, and they think that that’s the best thing to
do, and some of them haven’ta c c e p t e dt h a tt h eb e s t
thing to do is put patients into SPARE (Investigator).
Most recruiters felt they should accept any expressed
preferences, and were reluctant to challenge patients’
preferences:
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much on the patient. If I feel that they’re the sort of
person who could cope with the uncertainty, then I’ll
say to them, ‘we’re not going to know unless research
is done’ or say to them, ‘it wouldn’tb eb e i n gl o o k e d
at if there wasn’t very good evidence showing that
radiotherapy was potentially as good’,b u ty o uc a n
tell when you’re speaking to patients, if they abso-
lutely want the bladder removed, you’re not going to
be able to sway them, and I don’t think it would be
ethical to try to be honest. If they’re adamant, no
they want it over with, they want it out, they want it
gone, then I don’t think it’s ethical to push, because if
it wasn’t the trial, they wouldn’t be having radiother-
apy pushed on them anyway, and I don’t feel it’s
ethical to push them any further (Nurse, Recruiter).
Most recruiters did indicate their own treatment pre-
f e r e n c e sa n dm o s ta l s oi n s i s t e dt h a tt h e yd i dn o tt r a n s -
fer these onto patients:
P5: I quite like the idea of selective bladder preserva-
tion with radiotherapy, it doesn’t mean I sell that
over and above everything else to my patients (Oncol-
ogist, Recruiter).
P6: If it was me (sighs) yeah, I’dp r o b a b l yw a n ti t
taken out, but I can be very positive (laughs) when I
need to be, I’m very pro research (...) I don’t think my
preferences would affect what I say because I keep
that inside my head. I’m very good at, you know, at
the end of the day my job is to promote research,
and I think it’s a question that needs answering and
I truly don’t think that my personal views would
even come into it (Nurse, Recruiter).
Later, this same recruiter continued:
P6: I think they’ve got to be pro radiotherapy to be
able to go in the trial. I certainly wouldn’tt r ya n d
influence someone at all (Nurse, Recruiter).
It is clear from other research that the personal views
of recruiters can be transmitted to patients, often unwit-
tingly [17]. In the following extract, this same recruiter
continues to convey their personal views and also shows
a willingness to act on judgements about patients that
might explain why less than half of patients eligible for
SPARE had the trial explained to them:
P6: I think if you’ve got a very anxious, nervous patient,
they’re not going to go on the study anyway, because
they’d rather just have it taken out and be done with it.
I think you’ve got to have quite a confident person to be
on a trial like this. I can’t say to someone, ‘I’m going to
give you gold standard treatment and we’re going to
look at extra’, they’re either having the gold standard
treatment or an experimental treatment. You’re asking
someone to give it a try, and whilst I think that’s great,
and we need to do it, it’s a lot for someone to take on
board (Nurse, Recruiter).
A further factor that emerged from the interviews was
that centres sometimes appeared to take on a ‘collective’
preference - one that represented the views of most staff
in the centre. Two out of the four centres interviewed
gravitated to a collective view - one for surgery and the
other for SBP. The screening logs from these two cen-
tres also reflected the collective preference of the centre.
In the centre that appeared to be pro-SBP, 7 out of 9
patients who declined did so because of a preference for
the bladder preservation arm or because they did not
want surgery. Similarly, in the centre that appeared to
be pro-surgery, 4 out of 6 patients who declined opted
for surgery.
Plan of action - Phase II
An overview of the findings above was presented to the
SPARE TMG and the following actions were agreed:
(a) Feasibility study to continue
It was agreed that the recently published review article
[5] gave new impetus to the need for the SPARE trial.
Interview data showed that investigators and recruiters,
particularly based in oncology, continued to view this as
a ni m p o r t a n tq u e s t i o n ,a n dt h a tt h e r ew a ss t r o n gc o m -
mitment from clinicians and recruiters.
(b) Changes to design and paperwork
It was accepted that the trial design was too complex to
be easily articulated and that some of the terminology in
the PIS was potentially confusing. Intensive discussion
of the intended design led to the construction of a sim-
pler version of the study flowchart (Figure 1) which was
then issued to recruiters so that they could provide a
clearer articulation of the trial. The consent for che-
motherapy was separated from the consent for SPARE
in response to recruiters indicating that patients were
given too much information about various aspects of
the trial at the same time. The randomisation period
was also simplified and clarified so that patients could
be randomised at any time before the three cycles of
chemotherapy rather than during the second cycle.
The recruitment study team drafted a new, shorter and
clearer PIS which removed the ‘loaded’ terminology,
explained the simplified study outline and included the
new flowchart. The PIS also included a clearer explana-
tion of randomisation and a new table comparing evi-
dence about side effects and outcomes of each treatment.
These changes drew on findings from the interviews and
the content of PIS’ from other RCTs.
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It was agreed that the involvement of many different clin-
icians and researchers during the sensitive recruitment
period was not helpful to the trial. Clinical centres were
asked to identify two Lead Recruiters (LRs) per site
whose responsibilities would be to act as the focus for
SPARE recruitment activity. The LRs were also advised
t os e ei ft h e yc o u l da r r a n g eas p e c i f i c‘recruitment
appointment’ about 7-10 days after the chemotherapy
discussion, with the aim of providing full information
about the trial and treatments, and obtaining consent for
participation and randomisation if possible. It was also
recommended that trial participants should be referred
to the respective specialists after randomisation rather
than before to ensure consistency of information and to
avoid information overload (Figure 2).
(d) Eligibility
Problems with finding sufficient numbers of eligible
patients emerged as a critical issue, especially during the
training and feedback process:
P9: It’s funny we just seem to keep finding extra ways for
patients not to be eligible. It’s quite bizarre really and it’s
gone beyond despair and got to be a bit of a joke in a way,
every time we think we’ve got a good candidate, there’s
something going on (laughs) (Oncologist, Recruiter).
P15: When we went back and had a look at it, the
consultant came back towards the surgeon and said,
‘oh there isn’t as many as I originally thought’,a n d
sort of admitted that perhaps he’d overestimated the
amount of patients to when he’dg o n eb a c ka n dh a d
another look, so I don’t think we, they just don’t
come through that regularly (training teleconference).
The possibility of relaxing certain inclusion criteria
was discussed with the TMG but it was decided that
these could not be changed without invalidating the
aims of the RCT.
(e) Training and individual feedback
In order to address the issues related to treatment prefer-









































































*If the three cycles of chemotherapy do not clear your cancer well, you won’t receive 
a fourth cycle and will have surgery as soon as possible, whichever group you are in.
NEW  OLD 
Figure 1 SPARE trial treatment scheme flowchart in Patient Information Sheet: Old and New. Following findings from the qualitative
recruitment investigation that the SPARE trial was difficult to explain, a simpler version of the study flowchart was incorporated in all study
documentation including the Patient Information Sheet (PIS). The old and new versions of the study flowchart in the PIS are provided in
Figure 1.
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x  Do not give much information about SPARE at this point 
x  If patient requests information about the treatment 
options, to state them briefly and give the SPARE-PIS to 
read later and come back with questions. 
Patient referred from GP/Multi-disciplinary team/New patient clinic 
Lead Recruiters (LRs) 
identified at each centre 
(one lead clinician and one 
research nurse) 
Diagnosis given (LR to liaise with 
person giving diagnosis) 
1.  Chemotherapy discussion and handing out of SPARE-PIS if 
patient agrees to chemotherapy (if it is not the LR who does this, 
LR to liaise with person doing the discussion to hand out PIS 
and refer to LR for recruitment appointment) 
2.  Organising the recruitment appointment within 7-10 days of 
chemotherapy discussion (this is to be arranged with the patient 
preferably during or shortly after the chemotherapy discussion) 
Recruitment appointment with LR (Recruiters to refer to ‘Tips for 
recruitment appointment structure’) 
If patient agrees, consent and randomisation at same 
appointment (randomisation period: anytime before check 
cystoscopy following cycle 3 of chemotherapy) 
Referral to specialists depending on arm randomised to (this 
requires that LRs are aware of all aspects of the two treatment 
arms as referral is after randomisation) 
Figure 2 Recommendations to streamline the SPARE trial recruitment pathway. Following findings from the qualitative recruitment
investigation that the SPARE trial recruitment pathway was complicated and involved a number of people, suggestions to streamline the
recruitment pathway were provided to recruitment centres. The schematic representation of the suggestions as distributed to centres is shown
in Figure 2.
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sessions were organised. The first two were held at con-
ferences (British Uro-oncology Group Annual Meeting
and National Cancer Research Institute Conference). The
content included a summary of the findings from Phase
I, the changes suggested to study documentation, and
some simple ‘tips’ about recruitment drawn from the
ProtecT documents [10]. There were then four recruit-
ment training sessions with particular centres (two by
teleconference and two face-to-face). These sessions
included examples of good practice and recruitment ‘tips’
included those that were transferable from the ProtecT
study and some developed specifically for the SPARE
trial. Transferable tips included the need to let patients
know that they were eligible for both treatment arms
and that the evidence for which treatment was better
was still unknown [16], systematically eliciting and
addressing patient preferences/concerns, and the use of
strategies such as readily ceding the floor when overlap-
ping speech occurs to enable patients to express con-
cerns that may otherwise be concealed [17]. Tips specific
to the SPARE study included providing information
about chemotherapy separately from the radiotherapy/
surgery treatment options, the practicalities of imple-
menting the streamlining of the recruitment pathway,
and options for addressing patient preferences using case
studies provided by SPARE recruiters. Individual feed-
back on the content of audio-taped recruitment encoun-
ters was given to the recruiters who provided tape-
recordings.
Outcome of Phase II
A table showing the major findings and the subsequent
changes and methods of implementation provides an
overview of the potential impact of the recruitment
study (Table 3). The extremely tight timelines for the
study meant that evaluating the impact of the changes
made in Phase II was difficult. At the request of the
Independent Data Monitoring Committee (IDMC) a
joint meeting of the IDMC and TSC was held in Janu-
ary 2010 to review recruitment in light of the target of
six patients per month ahead of the submission of the
annual report to the funding body. Although informed
of the alterations to SPARE and the training imple-
mented as a result of this study, with average recruit-
ment of one patient per month, the TSC considered
that the issues related to restricted patient eligibility
were insurmountable and advised closure of the
SPARE trial in February 2010. As this was only six
weeks after the last training session and included the
winter holiday period, there were only very limited
data that could indicate whether the changes made
might have had an impact.
Feedback was sought about the various changes and
tips during the training sessions and there was overall
agreement that these had been helpful:
P13: The change in when you can randomise
patients, that’s made a big difference, having that lit-
tle bit more playing time (training teleconference).
P18: Well I noticed that it (flowchart) was much
simplified, simplified, and much easier, yes (training
teleconference).
P9: I quite like the idea of bringing randomisation
further forward, I think it’si na no d dp l a c ea tt h e
moment (...). I like the flow sheet, figure 1, diagram of
SPARE treatment is a great improvement. I believe
the patients on the previous one that had the four
way tracks down as it were, I think that’sab i gh e l p
(...). In the latest version of the information sheet,
which I think is version 6 with that lovely table on
the end which has the pros and cons, if we gave that
to patients before a surgeon spoke to them, before a
radiotherapist spoke to them, heaven’s sake, before a
medical oncologist spoke to them, then we might
have some patients who better appreciated the diffi-
culties involved (Oncologist, Recruiter).
Most recruiters felt that the recommendations to
streamline the recruitment pathway were sensible and
feasible in their centres:
P9: I like the idea fundamentally, it fits in with a lot
of things, a lot of conclusions I’ve been coming to
(Oncologist, Recruiter).
P10: I can see the reasoning behind that yeah. I can’t
see that being a problem here no (Surgeon, Recruiter).
The main focus of the training sessions was to enable
recruiters to manage treatment preferences and there
w a ss o m ee v i d e n c et h a ti th e l p e dr e c r u i t e r sf e e lm o r e
confident in this area:
JLD: Do you feel comfortable doing that (addressing
preferences)?
P17: I haven’td o n ep r e v i o u s l y ,b u tIt h i n ka f t e r
speaking to you today,( y o u )expressing that it is a
common problem and that they might not be fully
i n f o r m e da b o u ti t ,It h i n kI ’ll probably feel a bit
more confident in approaching it and discussing both
options and enlightening them on both options (train-
ing teleconference).
In terms of numbers of new recruits, there was insuffi-
cient time after the training sessions to be conclusive.
Two centres, one that had recruited only two patients
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expressed renewed enthusiasm after attending the train-
ing sessions and then had discussions with three eligible
patients, one of whom agreed to randomisation shortly
before the closure of the trial.
Discussion
Qualitative research methods were used to investigate rea-
sons for low levels of recruitment to the SPARE trial
which compared two very different treatments for bladder
cancer: surgical removal of the bladder versus a policy of
radiotherapy to preserve the bladder in most cases. Within
three months, a combination of documentary analysis, in-
depth interviews with investigators and recruiters, simple
analysis of eligibility/screening logs, and tape-recording of
a small number of recruitment interactions clearly identi-
fied four major barriers to recruitment in relation to the
design and conduct of the trial, and another major obsta-
cle in the form of strongly expressed patient treatment
preferences. A plan to improve recruitment was drawn up
and various changes were implemented (new PIS and
study flowchart, streamlining of the recruitment pathway),
followed by dedicated training sessions and information to
disseminate the changes and tackle the issue of treatment
preferences. One issue was intractable - the shortage of
eligible patients - and this contributed to the TSC’sd e c i -
sion to close the trial (on the grounds that the large phase
III trial, powered for non-inferiority of SBP, would not be
feasible) [18]. Several comments were made by recruiters
and investigators that the changes were plausible and the
training sessions acceptable and useful, and there was also
an indication in two centres that renewed enthusiasm had
led to new ways of working and might have been able to
generate new trial recruits, but a clear evaluation of the
outcome of the plan to improve recruitment could not be
undertaken. The scale of the recruitment target and the
lack of eligible patients proved fatal to the SPARE RCT.
This recruitment investigation built on considerable
previous research, particularly the development of a
complex recruitment intervention based on the ProtecT
Table 3 SPARE trial qualitative recruitment investigation - mapping findings and changes
Key issues Findings Changes/recommendations Aspect of trial changed/
recommendation for
Implementation




Easy explanation of trial Recruiter-patient interaction
bTraining session









Information overload Two-stage information provision
(chemo and post-chemo)
Recruitment and pre-recruitment





























Preferences Patient preferences influenced by













athese changes of the PIS and protocol were done together.
bthese aspects were done at various points in the study, but it was not possible to monitor their implementation because of the closure of the trial.
The major findings and the subsequent changes and methods of implementation of the qualitative recruitment investigation are shown in Table 3.
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in the Quartet study (Qualitative Research to Improve
Recruitment to Randomised Controlled Trials) [7]. The
SPARE study has enabled further refinement of the
intervention. Several problems that arose in these pre-
vious studies were avoided in the SPARE study by, for
example, ensuring ethical approval for the qualitative
work was integrated into the trial, interviews were con-
ducted as rapidly as possible, documentary analysis was
undertaken to investigate the evidence for the trial still
being an important question and the PIS was scrutinised
to ensure it provided a simple and balanced view of the
treatment options and a clear explanation of
randomisation.
Some of the issues identified early in the recruitment
investigation required changes that were fairly unproble-
matic to implement. For instance, the finding that the
complexity of the trial design was proving to be a major
obstacle to recruitment provided an ideal opportunity to
discuss the clear questions being addressed at the heart
of the trial that could then be captured in a new flow-
chart and PIS. Essentially, SPARE was a comparison of
surgical removal of the bladder versus an attempt to
retain the bladder. The complex issues of chemotherapy,
timing of cystoscopy and also the final determination of
whether surgery would be necessary in the SBP arm
c o u l dt h e nb em o r ee a s i l yd e s c r i b e dw i t h i nt h a t
framework.
The discovery of unexpectedly ‘loaded’ terminology in
the interviews and recordings of appointments was simi-
lar to the ProtecT study, although the actual ‘loaded’
terms were different. This shows the importance of
understanding how common medical terms are per-
ceived in particular circumstances, and how their avoid-
ance might improve recruitment [16]. In the SPARE
trial, it was important to convey that cystectomy was
the long-established treatment, and that the policy of
radiotherapy to allow selective bladder preservation was
a newer concept that potentially offered a less invasive
treatment - and that a comparison of the two
approaches was urgently required. This became trans-
lated to surgery being the ‘gold standard’ and SBP
‘experimental’ and thus led to the reinforcement of
treatment preferences that were already strong because
of the differences perceived between the arms [6]. Inter-
estingly, the ‘loaded’ terms could be detrimental or sup-
portive, depending on the direction of the underlying
preference.
The emergence of patients’ treatment preferences as a
major barrier to recruitment was not unexpected
because of the similarity to the surgery/radiotherapy
comparison in the ProtecT study and in two of the
Quartet trials [7]. These preferences were also identified,
to some extent, through screening logs collected by the
trial team [19] and in the qualitative patient interview
study [6]. Patients’ treatment preferences have been
identified as a barrier to recruitment in many systematic
reviews [20-23]. However, in the ProtecT study complex
recruitment intervention, training was given to enable
recruiters to learn how to elicit, understand and then,
where appropriate, address patient preferences [17],
leading to a clear increase in randomisation and
informed consent [16]. There were examples in the Pro-
tecT study of recruiters unwittingly passing on their
own biases to patients [16], and this was also found in
the SPARE trial, but another concept also emerged here
- that of the development of a shared ‘centre preference’.
Within particular centres, members of the clinical team
had preferences themselves for a particular treatment,
and then (mostly unwittingly) transmitted these to
patients. This was evident ini n t e r v i e w sa n dw a sc o n -
firmed by screening logs in which patients in particular
centres tended to decline participation because of a pre-
ference for one arm or the other. The development of
different ‘centre’ preferences is not unexpected when
there is uncertainty over treatments - so called ‘commu-
nity equipoise’ [24,25] - but unless this is tackled it is
problematic for trial recruitment.
The SPARE training sessions drew on generic recruit-
ment tips from the ProtecT and Quartet study findings.
The development of specific tips for SPARE was hin-
dered by the failure to collect audio recordings of
appointments - only four were available. The reasons for
the failure of recruiters to record themselves despite
indicating a willingness to do so were not specifically
elicited in this study, but are likely to be similar to those
found elsewhere, including recruiters feeling daunted by
the prospect of being scrutinised/criticised, and fearing
that their role as the patient’s advocate might be com-
promised by having to ask about the recording [7]. As
this is such a crucial aspect for understanding recruit-
ment interactions, there needs to be more research in
future to counter these fears and increase the number
of recordings.
An important contribution of the SPARE recruitment
study was to show that it was possible to apply a rapid
adaptation of a ProtecT-like recruitment intervention,
using primarily qualitative research methods. The key
issues were identified within three months, a plan of
action agreed in month four and implemented in
months five to seven.
Screening logs provided helpful information about the
application of eligibility criteria and the number of
potential participants. The SPARE trial conformed with
all the Good Clinical Practice (GCP) criteria and was
extremely well co-ordinated. The TMG was aware that
recruitment was difficult, but it was the targeted qualita-
tive research that elicited the underlying barriers to
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enced in explaining the design simply and the interac-
tions between clinical teams in centres that created
‘centre preferences’.
The SPARE recruitment study has identified a number
of issues relevant for the future design of trials. It is
important, for example, to reduce the apparent com-
plexity of the trial by encapsulating the design in a rela-
tively simple flowchart. This then helps recruiters to be
clearer in their presentation of the trial. The SPARE
study also indicated several issues relevant to the future
application of recruitment interventions that incorporate
qualitative research. Although the recruitment investiga-
tion and its intervention were completed and implemen-
ted quickly, the trial closed before its findings could be
fully evaluated, so the optimal time for such studies
might be early in the trial design or feasibility stage - as
in the ProtecT study [16]. Qualitative research that is
initiated at later stages faces a number of challenges [7].
However, the time-lines for the intervention are now
clearer from this study, and so targeted investigations
might be possible if there were at least 18 (or better 24)
months of recruitment time remaining. Another factor
of importance for the future for trials with very different
arms is to explore the need for joint lead investigators
representing each clinical speciality. The intervention
part of the study would have had much more and earlier
immediate relevance for SPARE if it had been possible
to obtain audio-recordings of recruiter-patient interac-
tions. This aspect should perhaps have greater promi-
nence in future interventions. The success of the
qualitative investigation in understanding the key
recruitment issues inside three months bodes well for
future applications. It is likely that these sorts of studies
are more useful for trials that involve very different
treatment arms - as in ProtecT and SPARE. This was
also true of the Quartet trials, although several of those
were ‘difficult’ for other reasons [7,8]. Such interventions
are unlikely to be necessary in placebo-controlled drug
trials, or those involving different methods of delivery of
the same treatment. There are, however, increasing
numbers of complex and challenging trials that may
provide opportunities for targeted recruitment
interventions.
Conclusions
In conclusion, this study has demonstrated the adapt-
ability of the ProtecT intervention and contributed
towards refining the methods for future recruitment
interventions using qualitative research methods. It
has underlined the role of such studies in elucidating
challenges to recruitment in trials with very different
treatment arms, and has given some hope that these
challenges may not be insurmountable if the time
required for the intervention to take effect is provided.
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